Nevada bill targeting the cost of diabetes drugs was stripped of a key provision that would have required drug makers to provide refunds to patients and insurers if wholesale prices rose by more than a medical component of the Consumer Price Index each year.

The move came after the state Legislative Counsel Bureau issued a memo on Monday saying the bill could have violated the Interstate Commerce Clause, which restricts states from regulating interstate commerce, and the Supremacy Clause, which says that federal law supersedes state law when a conflict exists between the two.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy